

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/081,713	02/21/2002	Carlos R. Plata-Salaman	ORT-1583	1258
27777 7.	590 09/01/2004		EXAMINER	
PHILIP S. JOHNSON			SPIVACK, PHYLLIS G	
JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, NJ 08933-7003			ART UNIT	PAPER NUMBER
			1614	
			DATE MAILED: 09/01/200	4

Please find below and/or attached an Office communication concerning this application or proceeding.

A. P. G. B.	Applicant(s)				
Application No.	Applicant(s)				
10/081,713	PLATA-SALAMAN ET AL.				
Examiner	Art Unit				
Phyllis G. Spivack	1614				
ppears on the cover sheet w	vith the correspondence address				
LY IS SET TO EXPIRE 3 No. 1.136(a). In no event, however, may a seply within the statutory minimum of the d will apply and will expire SIX (6) MO atte, cause the application to become A ling date of this communication, even in	reply be timely filed irty (30) days will be considered timely. NTHS from the mailing date of this communication. ABANDONED (35 U.S.C. § 133).				
<u>March 2004</u> .					
Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
on. rawn from consideration. /or election requirement.					
ner.	·				
0) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.					
	g(s) is objected to. See 37 CFR 1.121(d). ed Office Action or form PTO-152.				
gn priority under 35 U.S.C. Ints have been received. Ints have been received in It iority documents have been It is in the certified copies no	Application No n received in this National Stage				
~□·· ·	· Cummery (DTO 442)				
Paper No	v Summary (PTO-413) o(s)/Mail Date f Informal Patent Application (PTO-152)				
	Examiner Phyllis G. Spivack Depars on the cover sheet was a ply within the statutory minimum of the dwill apply and will expire SIX (6) MO dwill apply and will expire SIX (6) MO ding date of this communication to become A sing date of this communication, even a section is non-final. The saction is non-final ance except for formal manage in the same application. The saction requirement is a section requirement. The saction is required if the drawing is required if the drawing is required if the drawing is required if the attached and priority under 35 U.S.C. and the shave been received in it is that the same is the same been received in it is that the same is the same been received in it is that the same is the same been received in it is that the same is the certified copies not save been received in the same been received. A) Interview Paper No. S) Interview Paper				

Application/Control Number: 10/081,713

Control Hamber: 10,001,7

Art Unit: 1614

Applicants' Amendment filed March 12, 2004 is acknowledged. Claims 1-25 are pending.

The rejection of record in the last Office Action under 35 U.S.C. 112, second paragraph, directed to the inclusion of parenthetical subject matter in claims 1, 5, 11, 20 and 23 is withdrawn following their deletion in the claims.

Claims 1-25 were rejected in the last Office Action under 35 U.S.C. 112, first paragraph, as containing subject matter that was not described in the specification in such a way as to enable one skilled in the art to practice the invention. The specification provides no support for preventing or treating anxiety disorders.

Applicants argue the specification teaches how to make and use the claimed invention on pages 16-18, and no persuasive reasons or evidence are given to support an assertion of lack of enablement.

Applicants' arguments have been given careful consideration but are not found persuasive. The rejection is repeated for the reasons of record.

A review of pages 16-18 of the specification discloses discussions of modes of administration, optimal dosage ranges and dosing regimens. There is no discussion directed to preventing or treating a subject having an anxiety disorder comprising administering a compound of instant formulas I or II. Further, Applicants have failed to provide guidance as to which particular compound would be preferred for preventing or treating the various anxiety disorders encompassed in the claim language.

No claim is allowed.

Application/Control Number: 10/081,713 Page 3

Art Unit: 1614

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication should be directed to Phyllis G. Spivack at telephone number 571-272-0585.

Phyllis G. Spivack
Primary Examiner

Art Unit 1614 PHYLLIS SPIVACK PRIMARY EXAMINER

August 28, 2004